<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We analyzed cytosolic high-Km 5'-nucleotidase (cN-II) and deoxycytidine kinase (dCK) <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in bone marrow mononuclear cells (BMMNC) of patients with high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) using quantitative real-time polymerase chain reaction (rt-PCR) </plain></SENT>
<SENT sid="1" pm="."><plain>At diagnosis, the cN-II <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of patients was higher than that of healthy volunteers, but the dCK <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression showed no significant difference </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with ara-C-containing chemotherapies whose BMMNC showed a high level of cN-II expression (greater than the median value) had shorter median overall survival (15 months versus 22 months, p&lt;0.01) and shorter median post-chemotherapy survival (10 months versus 16 months, p=0.012) </plain></SENT>
<SENT sid="3" pm="."><plain>These data suggest that the expression level of cN-II <z:chebi fb="2" ids="33699">mRNA</z:chebi> might be a prognostic factor of high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>